Sign In
Section Navigation
Common TitleTARGET
Official Title Combivir, Abacavir (1592U89), Amprenavir (141W94) Triple Antiretroviral, Experienced Patient Trial
Phase Phase IV
ClinicalTrials.gov NCT00002217
Categories Treatment-Experienced
Funding
IndustryGlaxo Wellcome
References
  • Henry K, Wallace RJ, Bellman PC, et al. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study. J Infect Dis. 2001;183:571-8.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.